Evidence map›Paper›PMID 36511516›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2023

Mitoquinone mesylate attenuates pathological features of lean and obese allergic asthma in mice.

Ravishankar Chandrasekaran, Sierra R Bruno, Zoe F Mark, Joseph Walzer, Sarah Caffry, Clarissa Gold, Amit Kumar, Nicolas Chamberlain, Isabella M Butzirus, Carolyn R Morris and 8 more

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Obesity-driven airway eosinophilia and neutrophilia in asthma.The Journal of asthma : official journal of the Association for the Care of Asthma · 2025
    Review
  4. Review
  5. Obesity: Next game changer of allergic airway diseases?Clinical and translational medicine · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Ravishankar ChandrasekaranDepartment of Medicine, University of Vermont, Burlington, Vermont.
Sierra R BrunoDepartment of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont.
Zoe F MarkDepartment of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont.
Joseph WalzerDepartment of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont.
Sarah CaffryDepartment of Medicine, University of Vermont, Burlington, Vermont.
Clarissa GoldDepartment of Biology and Vermont Biomedical Research Network Proteomics Facility, University of Vermont, Burlington, Vermont.
Amit KumarDepartment of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont.ORCID 0000-0002-7043-3798
Nicolas ChamberlainDepartment of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont.
Isabella M ButzirusDepartment of Medicine, University of Vermont, Burlington, Vermont.
Carolyn R MorrisDepartment of Medicine, University of Vermont, Burlington, Vermont.
Nirav DaphtaryDepartment of Medicine, University of Vermont, Burlington, Vermont.
Minara AliyevaDepartment of Medicine, University of Vermont, Burlington, Vermont.
Ying-Wai LamDepartment of Biology and Vermont Biomedical Research Network Proteomics Facility, University of Vermont, Burlington, Vermont.
Albert van der VlietDepartment of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont.ORCID 0000-0003-0923-0016
Yvonne Janssen-HeiningerDepartment of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont.ORCID 0000-0002-2735-8745
Matthew E PoynterDepartment of Medicine, University of Vermont, Burlington, Vermont.ORCID 0000-0002-7578-4570
Anne E DixonDepartment of Medicine, University of Vermont, Burlington, Vermont.
Vikas AnathyDepartment of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont.ORCID 0000-0003-4288-912X
University of Vermont · US

Funding

Vermont INBRE Administrative Supplement 2024 AWD 118P20GM103449 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Julie Dragon · 2012 to 2026
$58.4M
Multidisciplinary Training in Lung BiologyT32HL076122 · NHLBI · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI IRVIN, CHARLES G, POYNTER, MATTHEW E · 2004 to 2023
$6.1M
Obese Allergic Asthma and the Impact of Weight Loss on Airway Epithelial FunctionR01HL133920 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI DIXON, ANNE E, POYNTER, MATTHEW E · 2016 to 2020
$3.9M
Mitochondrial Redox Perturbations in Obese Allergic AsthmaR01HL136917 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI ANATHY, VIKAS, DIXON, ANNE E · 2018 to 2022
$3.6M
Endoplasmic Reticulum Stress Signaling in Allergen-induced Airway RemodelingR01HL122383 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI ANATHY, VIKAS · 2015 to 2023
$3.5M
DUOX1 and Mitochondria in Obese AsthmaR01HL138708 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI VAN DER VLIET, ALBERT · 2017 to 2020
$2.1M
Ketone Body Supplementation in Obese AsthmaR01HL142081 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI POYNTER, MATTHEW E · 2018 to 2021
$1.8M
Unfolded protein response in Influenza virus infection and inflammationR01HL141364 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI ANATHY, VIKAS · 2019 to 2022
$1.6M
Nikon A1R-ER Confocal Microscope for the Microscopy Imaging CenterS10OD025030 · OD · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI TAATJES, DOUGLAS J. · 2018 to 2018
$557k
NHLBI NIH HHS R01 HL122383NHLBI NIH HHS R01 HL133920NHLBI NIH HHS R01 HL136917NHLBI NIH HHS R01 HL138708NHLBI NIH HHS R01 HL141364NHLBI NIH HHS R01 HL142081NHLBI NIH HHS T32 HL076122NIGMS NIH HHS P20 GM103449NIH HHS S10 OD025030
6 · The paper itself

Abstract

Obesity is associated with severe, difficult-to-control asthma, and increased airway oxidative stress. Mitochondrial reactive oxygen species (mROS) are an important source of oxidative stress in asthma, leading us to hypothesize that targeting mROS in obese allergic asthma might be an effective treatment. Using a mouse model of house dust mite (HDM)-induced allergic airway disease in mice fed a low- (LFD) or high-fat diet (HFD), and the mitochondrial antioxidant MitoQuinone (MitoQ), we investigated the effects of obesity and ROS on HDM-induced airway inflammation, remodeling, and airway hyperresponsiveness (AHR). Obese allergic mice showed increased lung tissue eotaxin, airway tissue eosinophilia, and AHR compared with lean allergic mice. MitoQ reduced airway inflammation, remodeling, and hyperreactivity in both lean and obese allergic mice, and tissue eosinophilia in obese-allergic mice. Similar effects were observed with decyl triphosphonium (dTPP

Indexed as

AsthmaEosinophiliaAnimalsDisease Models, AnimalInflammationLungObesityOrganophosphorus CompoundsPyroglyphidaeUbiquinoneDTPPmitoquinoneOrganophosphorus CompoundsUbiquinoneER stressMitoQobese allergic asthma

Identifiers

PMID36511516
PMCPMC9902225
OpenAlexW4311291245

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.